Ashlee Rowe studies grasshopper mice that shrug off bark scorpion stings. OU has filed a patent on her redesigned peptides, which are not yet tested.
Recap by typeshit. Full story at The University of Oklahoma.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
She points to work shown at ADA 2026 and published in Nature Communications suggesting semaglutide may improve epigenetic aging markers.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
In 485 insulin-naive type 2 diabetes patients, icodec plus semaglutide cut HbA1c more and trimmed weight while glargine users gained 3.81 kg, though GI side effects ran higher.
News-Medical reports that the diabetes and weight loss medicines may also lower the chance of serious complications in the recovery period after an operation.
Loading…